Enjoy complimentary customisation on priority with our Enterprise License!
The structural heart devices market share is expected to increase by USD 7.60 billion from 2021 to 2026, and the market’s growth momentum will accelerate at a CAGR of 10.03%.
This market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers market segmentation by method (replacement procedures and repair procedures) and geography (North America, Europe, Asia, and Rest of World (ROW)). The market report also offers information on several market vendors, including Abbott Laboratories, AFFLUENT MEDICAL SA, Artivion Inc., AtriCure Inc., Boston Scientific Corp., Braile Biomedica, CORONEO Inc., Edwards Lifesciences Corp., Getinge AB, Jc Medical Inc., Johnson and Johnson Inc., Lepu Medical Technology Beijing Co. Ltd., Lifetech Scientific Shenzhen Co. Ltd., LivaNova Plc, Medtronic Plc, Micro Interventional Devices Inc., NuMED Inc., Terumo Corp., TTK Healthcare Ltd., and W. L. Gore and Associates Inc. among others.
Download Report Sample to Unlock the Structural Heart Disease Treatment Devices Market Size for the Forecast Period and Other Important Statistics
Based on our research output, there has been a positive impact on the market growth during and post-COVID-19 era. The increasing prevalence of structural heart diseases is notably driving the structural heart disease treatment devices market growth, although factors such as high costs associated with structural heart disease treatment procedures may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the structural heart disease treatment devices industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Structural Heart Disease Treatment Devices Market Driver
The increasing prevalence of structural heart diseases is one of the key drivers supporting structural heart devices market growth. For instance, CHD is the most common type of birth defect. According to the CDC, around 40,000 babies in the US are affected by it each year. About 75% of babies born with it are expected to survive to one year of age. Thus, the increasing prevalence of CHD augments the demand for structural heart devices. According to the National Institutes of Health (NIH), in 2020, the degenerative abnormalities associated with severe aortic stenosis and mitral and tricuspid regurgitation were found in nearly 10% of the population aged 75 years and above. Therefore, the increasing ageing population in developed and developing countries is likely to increase the prevalence of structural heart diseases, which, in turn, will augment the growth of the global market during the forecast period.
Key Structural Heart Disease Treatment Devices Market Trend
Technological innovations in structural heart disease treatment are another factor supporting the structural heart devices market growth. For instance, a research report published in April 2019 reported that some bioengineers of the Boston Children's Hospital developed a robotic catheter using a novel sensor integrated with artificial intelligence (AI) and an image processing algorithm. This catheter was then tested on animal models for cardiac valve repair. It was observed that the robotic catheter was able to locate the leaky heart valve without a surgeon's guidance. The sensor used AI and image processing algorithms to reach the leaky heart valve for repair procedures. This demonstrated that the integration of AI and software algorithms in structural heart devices could increase the efficiency of surgical procedures and minimize the complication and overall cost of the surgery. Such developments will drive the growth of the global market during the forecast period.
Key Structural Heart Disease Treatment Devices Market Challenge
High costs associated with structural heart disease treatment procedures are one of the factors hindering the structural heart devices market growth. Patients who receive mechanical heart valves are required to undergo long-term blood-thinning or anticoagulation drug therapy to minimize the risk of complications from blood clots. Thus, the direct costs associated with mechanical valves, including medication costs, testing costs, and costs of hospitalization related to bleeding and thromboembolism, are high. Meanwhile, bioprosthetic valves have a life of 7 years-20 years, after which the valve starts degenerating and must be replaced. This leads to multiple open surgeries for the replacement of the bioprosthetic valve. Thus, the cumulative cost of multiple operations will increase the cost burden of the treatment of patients during the forecast period. Therefore, the high cost associated with structural heart devices and procedures is hindering market growth.
This structural heart disease treatment devices market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.
Technavio categorizes the global structural heart devices market as a part of the global healthcare equipment market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the market during the forecast period.
The report analyzes the market’s competitive landscape and offers information on several market vendors, including:
This statistical study of the structural heart disease treatment devices market encompasses successful business strategies deployed by the key vendors. The structural heart disease treatment devices market is concentrated and the vendors are deploying growth strategies such as R&D activities to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The structural heart disease treatment devices market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Our report provides extensive information on the value chain analysis for the structural heart disease treatment devices market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
For more insights on the market share of various regions Request PDF Sample now!
41% of the market’s growth will originate from North America during the forecast period. The US is the key market for structural heart devices in North America. Market growth in this region will be slower than the growth of the market in Asia.
The increasing technological advances and product launches will facilitate market growth in North America over the forecast period. This structural heart devices market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
The outbreak of COVID-19 negatively impacted the demand for medical devices in North America. However, by January 2021, lockdown restrictions in various countries were lifted due to the initiation of large-scale vaccination drives. This has led to the resumption of business activities, including medical device manufacturing companies and preclinical studies. Such factors are expected to propel the demand for structural heart devices in North America during the forecast period.
To gain further insights on the market contribution of various segments Request PDF Sample
The market share growth by the replacement procedures segment will be significant during the forecast period. The replacement procedures segment is further segmented into SAVR procedures and TAVR procedures and accounts for the largest share of the global market. However, factors such as the increasing prevalence of structural heart diseases, new product launches, strong ongoing clinical trials for heart valve replacement procedures, and the growing investments by market players in developing new replacement devices will drive the growth of this segment during the forecast period. Meanwhile, the rising prevalence of aortic regurgitation, which occurs due to thickened ventricular walls, is a significant factor contributing to market growth.
This report provides an accurate prediction of the contribution of all the segments to the growth of the structural heart disease treatment devices market size and actionable market insights on post COVID-19 impact on each segment.
Bromhidrosis Disease Treatment market - The market share is expected to increase to USD 362.76 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 8.92%.
Heart Valve Repair and Replacement Devices market - The market share is expected to increase by USD 3.01 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 8.1%.
Heart Rate Monitoring Devices market - The market share is expected to increase by USD 418.41 million from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 11.81%.
Structural Heart Disease Treatment Devices Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 10.03% |
Market growth 2022-2026 |
$ 7.60 billion |
Market structure |
Concentrated |
YoY growth (%) |
9.5 |
Regional analysis |
North America, Europe, APAC, and ROW |
Performing market contribution |
North America at 41% |
Key consumer countries |
US, Germany, France, UK, Japan, and China |
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
Key companies profiled |
Abbott Laboratories, Becton, Dickinson and Co., Boston Scientific Corp., Braile Biomédica, CryoLife Inc., Edwards Lifesciences Corp., Lepu Medical Technology (Beijing) Co. Ltd., LivaNova Plc, Medtronic Plc, and MicroPort Scientific Corp. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Method
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.